| Literature DB >> 25669658 |
A Ramamoorthy1, M A Pacanowski, J Bull, L Zhang.
Abstract
Race and ethnicity can contribute to interindividual differences in drug exposure and/or response, which may alter risk-benefit in certain populations. Approximately one-fifth of new drugs approved in the past 6 years demonstrated differences in exposure and/or response across racial/ethnic groups, translating to population-specific prescribing recommendations in a few cases. When data from diverse populations were lacking, additional postmarketing studies were recommended. In this review we highlight several cases where race/ethnicity was central to regulatory decision-making.Mesh:
Substances:
Year: 2015 PMID: 25669658 DOI: 10.1002/cpt.61
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN: 0009-9236 Impact factor: 6.875